May 4, 2026
Latus Bio
Latus Bio develops gene therapy candidates, particularly for treating central nervous system (CNS) disorders using screened AAV capsids.
- Round
- Series A
- Amount raised
- $43M
- Lead investor
- 8VC
- Industry
- Biopharma
- Headquarters
- Philadelphia, United States
- Employees
- 11-50
- Website
- www.latusbio.com
- View profile →
Other investors
- DCVC Bio
Source: Crunchbase snapshot 2026-05-15